Related Experiment Video
Updated: Mar 23, 2026
08:36
Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
Published on: May 26, 2018
12.4K
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Pavithra Viswanath1, Myriam M Chaumeil1, Sabrina M Ronen1
1Department of Radiology and Biomedical Imaging, University of California San Francisco , San Francisco, CA , USA.
Frontiers in Oncology
|March 26, 2016
Summary
Mutant isocitrate dehydrogenase (IDH) enzymes reprogram cell metabolism, producing 2-hydroxyglutarate (2-HG) oncometabolite. Molecular imaging reveals these metabolic shifts, aiding in identifying new therapeutic targets for IDH-mutant tumors.
Area of Science:
- Oncology
- Metabolic Engineering
- Molecular Imaging
Background:
- Mutations in isocitrate dehydrogenase (IDH) are key drivers in various cancers, including low-grade gliomas and acute myeloid leukemia.
- Mutant IDH enzymes gain a neomorphic activity, converting α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), an oncometabolite that disrupts cellular epigenetics and differentiation.
- IDH mutations induce significant metabolic reprogramming beyond 2-HG production, with unique characteristics across different cancer types.
Purpose of the Study:
- To review the metabolic reprogramming in mutant IDH cells.
- To discuss the application of molecular metabolic imaging in understanding these metabolic alterations.
- To explore how metabolic imaging can inform therapeutic strategies and clinical monitoring of IDH-mutant tumors.
Main Methods:
- Review of existing literature on IDH mutations, metabolic reprogramming, and molecular imaging techniques.
- Analysis of how metabolic imaging elucidates the biological consequences of IDH mutations.
- Discussion of the translational potential of metabolic imaging for clinical applications.
Main Results:
- IDH mutations lead to profound metabolic reprogramming, characterized by 2-HG production and other altered metabolic pathways.
- Molecular metabolic imaging provides critical insights into the spatial and temporal metabolic changes within mutant IDH cells.
- Imaging data helps to differentiate mutant IDH tumors and monitor their response to therapy.
Conclusions:
- Metabolic reprogramming is a hallmark of IDH-mutant cancers, driven by both neomorphic 2-HG production and broader metabolic alterations.
- Molecular metabolic imaging is a powerful tool for dissecting the biology of IDH-mutant cells and identifying novel therapeutic vulnerabilities.
- Translational development of metabolic imaging methods holds promise for improved detection, monitoring, and treatment of IDH-mutant tumors.
